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Abstract The Japanese Gastric Cancer Association
(JGCA) started a new nationwide gastric cancer registry in
2008. Approximately 50 data items, including surgical
procedures, pathological diagnoses, and survival outcomes,
for 12004 patients with primary gastric cancer treated in
2001 were collected retrospectively from 187 participating
hospitals. Data were entered into the JGCA database
according to the JGCA Classiﬁcation of gastric carcinoma,
13th edition and the International Union Against Cancer
(UICC) TNM Classiﬁcation of malignant tumors, 5th edi-
tion by using an electronic data collecting system. Finally,
data of 11261 patients with gastric resection were analyzed.
The 5-year follow-up rate was 83.5%. The direct death rate
was 0.6%. TNM 5-year survival rates (5YSRs)/JGCA
5YSRs were 91.8/91.9% for stage IA, 84.6/85.1% for stage
IB, 70.5/73.1% for stage II, 46.6/51.0% for stage IIIA,
29.9/33.4% for stage IIIB, and 16.6/15.8% for stage IV.
The proportion of patients more than 80 years old was
7.0%, and their 5YSR was 48.7%. Compared to the JGCA
archived data, though the follow-up rate needs to be
improved, these data suggest that the postoperative results
of patients with primary gastric carcinoma have improved
in those with advanced disease and in the aged population
in Japan. All the authors belong to the Registration Committee of the Japanese
Gastric Cancer Association.
Y. Isobe (&)
Department of Surgery, National Hospital Organization Tokyo
Medical Center, 2-5-1 Higashigaoka, Meguro-ku,
Tokyo 152-8902, Japan
e-mail: isobey@mb.infoweb.ne.jp
A. Nashimoto
Department of Surgery, Niigata Cancer Center Hospital,
Niigata, Japan
K. Akazawa
Department of Medical Informatics, Niigata University Medical
and Dental Hospital, Niigata, Japan
I. Oda
Endoscopy Division, National Cancer Center Hospital,
Tokyo, Japan
K. Hayashi
Department of Surgery, Yamagata Prefectural Kahoku Hospital,
Yamagata, Japan
I. Miyashiro
Department of Surgery, Osaka Medical Center for Cancer
and Cardiovascular Diseases, Osaka, Japan
H. Katai
Department of Surgery, National Cancer Center Hospital,
Tokyo, Japan
S. Tsujitani
Department of Surgery and Science, Graduate School of Medical
Science, Kyushu University, Fukuoka, Japan
Y. Kodera
Department of Surgery, Nagoya University School of Medicine,
Nagoya, Japan
Y. Seto
Department of Gastrointestinal Surgery, Graduate School
of Medicine, University of Tokyo, Tokyo, Japan
M. Kaminishi
Department of Surgery, Showa General Hospital,
Tokyo, Japan
123
Gastric Cancer (2011) 14:301–316
DOI 10.1007/s10120-011-0085-6Keywords Gastric cancer  Registry  Survival rate 
Japan
Introduction
From 1998, the Japanese Gastric Cancer Association
(JGCA) began conducting a nationwide gastric cancer
registration project by using electronic data collecting
systems. Detailed survival analyses of 8851 patients with
primary gastric cancer treated in 1991 were reported in
2006 [1]. However, this nationwide registry was suspended
because of several issues such as the operation of the Act
Concerning Protection of Personal Information, revision of
the JGCA classiﬁcation for gastric cancer, and rapid
changesintheinformationtechnology(IT)environmentatthe
member hospitals. After a period of 10 years in which the
programwasinactive,theregistrationcommitteeoftheJGCA
startedanewregistrationprogramtocollectanonymizeddata
simply, correctly, and quickly, in 2008 [2, 3]. Based on this
program, we investigated the survival outcomes of patients
with primary gastric cancer treated in 2001.
Subjects, materials, and methods
In the 2008 JGCA nationwide registration program,
approximately 50 data items, including surgical proce-
dures, pathological diagnoses, and prognoses, for patients
with primary gastric carcinoma surgically treated in 2001
were collected retrospectively in 2008 by using custom-
made software. This software could be downloaded from
the JGCA website. The JGCA member hospitals could
participate in this project voluntarily.
The registration data of this system are listed in Table 1.
Deﬁnition and documentation of the items were based on
the Japanese (JGCA) Classiﬁcation of gastric carcinoma,
13th edition [4, 5] and the International Union Against
Cancer (UICC) TNM Classiﬁcation of malignant tumors,
5th edition [6]. These two classiﬁcations were not com-
patible with each other and items could not be converted
automatically. The JGCA T-category was identical to the
TNM classiﬁcation. On the other hand, in the JGCA clas-
siﬁcation, peritoneal metastasis and liver metastasis were
individually recorded as P- and H-categories, both of which
could be translated into the M-category in the TNM clas-
siﬁcation. Intraoperative peritoneal washing cytology (CY)
was an independent category in the JGCA classiﬁcation.
The JGCA N-category was deﬁned by the anatomical
extension of lymph node metastasis in association with the
location of the primary tumor, while the TNM N-category
was deﬁned by number of metastatic regional lymph nodes.
Items that are compatible in the JGCA classiﬁcation and
the TNM classiﬁcation, and items that are not compatible
are listed in Table 2 for convenience.
After the patients’ data were entered with the data entry
software, the patients’ names and other personal informa-
tion were removed from the exporting data set for privacy
protection. A compact disk containing the linkable anon-
ymous data was then mailed to the JGCA data center,
located at Niigata University Medical and Dental Hospital.
The accumulated data of the patients were reviewed and
analyzed by the JGCA registration committee. One- to
5-year survival rates (5YSRs) were calculated for various
subsets of prognostic factors by the Kaplan–Meier method.
Deaths of any cause observed during 5 postoperative years
were counted as events in the survival analysis. SPSS Ver.
15 software (SPSS, Chicago, IL, USA) was used for
Table 1 Registration data
Category Item
Personal
information
Name of hospital, serial no., case no., ID no.
a, age, sex
Follow-up Date of follow-up, survival situation, causes of death
Surgery Date of operation, approach, operative procedure, LN dissection (D), organs resected together with stomach, type of
reconstruction
Pathology Anatomical subsite, macroscopic type, size of tumor, histological type, depth of tumor invasion, ly, v, number of dissected
LNs, number of metastatic LNs, N, PM/DM, CY
JGCA ﬁnal
diagnosis
Depth of tumor invasion, adjacent structure involved, fN, H, P, M, curability, stage
UICC TNM
categories
T, N, M, stage
LN lymph node, ly lymphatic invasion, v venous invasion, N extent of LN metastasis (JGCA), PM/DM involvement of proximal and distal
margin, CY peritoneal cytology, fN extent of LN metastasis (ﬁnal diagnosis), H liver metastasis, P peritoneal metastasis, M distant metastasis,
JGCA Japanese Gastric Cancer Association, UICC International Union Against Cancer
a ID no. was not exported to the registration data set
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123statistical analyses. This nationwide registration program
was approved by the ethics committee of the JGCA.
Results
The data were collected from 187 participating hospitals
across the country. The geographical distribution of the
registered patients among Japan’s 47 prefectures is illus-
trated in Fig. 1. More than 1000 patients per year were
registered in the prefectures of Tokyo and Osaka; on the
other hand, the number of registered patients was less than
100 in 15 prefectures. The hospital volumes in the partic-
ipating hospitals are indicated in Fig. 2. The median hos-
pital volume was 66 patients per year.
Data of 13067 patients who had undergone surgery in
2001 for primary gastric tumors were eventually accumu-
lated. Of these, 88 patients with benign tumor or non-epi-
thelial tumor were excluded from the analysis. Ninety-four
patients who received endoscopic mucosal resection were
also excluded. Data of 881 patients lacked essential items.
Consequently, data of the remaining 12004 patients were
used for the ﬁnal analysis.
The results are shown in Tables 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
and 28; data in these Tables are for the total number of
patients, survival rates by year, standard error of 5YSR,
direct death within 30 postoperative days, numbers lost to
follow-up within 5 years, 5-year survivors, and main cau-
ses of death (such as local and/or lymph node metastasis,
peritoneal metastasis, liver metastasis, distant metastasis,
recurrence at unknown site, other cancer and other
Fig. 1 Geographical
distribution of the registered
patients
Table 2 Compatibility to convert JGCA classiﬁcation to TNM
classiﬁcation
Category JGCA 13th ed. TNM 5th ed. Compatibility
T 1–4 0–4 Compatible
N 0 0 Identical
1–3 1–3 Incompatible
M
a 0 0 Compatible
1 1 Compatible
H 0 None
1 M1 Compatible
P 0 None
1 M1 Compatible
CY 0 None
1 None
Stage IA IA Identical
IB, II, IIIA, IIIB,
IV
IB, II, IIIA,
IIIB, IV
Incompatible
Lymphatic
invasion
ly0 L0 Identical
ly1–3 L1 Compatible
Venous
invasion
v0 v0 Identical
v1–3 v1 Compatible
None v2
Histological
typing
Differentiated
type
G1–2 Compatible
Undifferentiated
type
G3–4 Compatible
Residual
tumor
Resection A–C R0–2 Incompatible
a JGCA M-category is deﬁned as distant metastases other than peri-
toneal, liver, or cytological metastases
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123disease). Figures 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14
show cumulative survival curves of patients stratiﬁed by
essential categories.
The 5YSR in the 12004 patients with primary gastric
cancer was 69.1% (Table 3; Fig. 3). Within 5 postoperative
years,1976patientswerelosttofollow-up;thefollow-uprate
was 83.5%. Of the 12004 patients, 11261 underwent gastric
resection;350wereunresected;andin393thetypeofsurgery
was not speciﬁed. Accordingly, the resection rate was 97.0%
(11261/11611). Sixty-three of the 11261 patients who had
undergone gastrectomy died within 30 postoperative days;
the direct death rate was 0.6% (Table 4; Fig. 4).
The most frequent cause of death in patients who
had received gastrectomy was peritoneal metastasis (n =
1040), followed, in descending order, by other diseases
(n = 501), liver metastasis (n = 357), recurrence at an
Table 3 Survival outcomes of primary cancer
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Primary
cancer
12004 86.4 78.7 74.1 71.1 69.1 0.4 95 1976 6588 309 1266 374 183 349 162 530 267
SE standard error, 5YSR 5-year survival rate, DD direct death, Lost to follow up lost to follow-up within 5 years, Alive 5-year survivors, L local recurrence
and/or lymph node metastasis, P peritoneal metastasis, H liver metastasis, M distant metastasis, R recurrence at unknown site, OC other cancer, OD other
disease, UK unknown
Table 6 Survival outcomes by age
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
\40 257 89.9 82.0 80.3 79.4 78.4 2.7 0 40 165 3 30 2 84104
40–59 3232 92.5 86.6 83.1 80.6 79.3 0.7 12 516 2095 60 274 58 48 66 13 54 48
60–79 6924 87.9 80.1 74.9 71.6 69.2 0.6 37 1129 3818 186 651 259 91 182 135 322 151
380 788 78.5 64.3 58.6 53.1 48.7 2.0 14 178 256 18 84 35 13 29 6 123 46
Table 4 Survival outcomes of resected cases and unresected cases
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Resected
cases
11261 88.6 80.9 76.2 73.0 70.9 0.4 63 1877 6354 267 1040 357 161 298 155 501 251
Unresected
cases
350 23.0 9.8 7.1 5.6 5.3 1.3 20 40 14 32 176 12 13 43 0 10 10
Fig. 2 Hospital volumes in the 187 participating hospitals
Table 5 Survival outcomes by sex
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Male 7828 88.4 80.7 75.6 72.3 70.0 0.5 47 1314 4348 190 646 299 112 205 138 403 173
Female 3419 88.9 81.1 77.5 74.6 73.0 0.8 16 562 1997 76 392 58 49 93 17 97 78
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123Table 9 Survival outcomes by histological diagnosis
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
pap 364 85.8 75.1 70.4 67.5 65.1 2.6 3 64 185 11 27 23 6 13 8 23 4
tub1 2752 95.2 91.1 87.9 85.3 83.5 0.7 5 519 1818 30 55 42 16 36 51 137 48
tub2 2997 89.2 81.4 76.3 73.1 70.6 0.9 20 537 1651 64 207 156 46 74 45 160 57
por1 1476 82.5 72.4 67.8 64.9 63.7 1.3 14 238 737 53 174 82 30 40 14 69 39
por2 1903 81.4 69.7 63.4 59.5 56.6 1.2 15 244 886 75 401 34 44 86 19 59 55
sig 1325 93.2 88.0 84.5 81.2 79.4 1.2 4 217 855 17 108 2 14 32 12 30 38
muc 231 81.5 68.8 60.4 53.7 51.2 3.4 1 24 100 9 54 5 1 10 3 19 6
Adenosquamous
carcinoma
6 50.0 33.3 33.3 16.7 16.7 15.2 0 0 1 0 2 2001 00
Squamous cell
carcinoma
5 60.0 30.0 0.0 0.0 0.0 0.0 0 1 0 2 1 0100 00
Miscellaneous
carcinoma
45 65.2 53.1 48.1 45.6 45.6 7.7 0 4 18 2 8 7220 11
Pap papillary adenocarcinoma, tub1 tubular adenocarcinoma, well-differentiated type, tub2 tubular adenocarcinoma, moderately differentiated type, por1
poorly differentiated adenocarcinoma, solid type, por2 poorly differentiated adenocarcinoma, non-solid type, sig signet-ring cell carcinoma, muc mucinous
adenocarcinoma
Table 8 Survival outcomes by macroscopic type
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Type 0 6085 97.5 95.7 93.7 91.8 90.3 0.4 12 1143 4401 20 45 23 23 32 100 217 81
Type 1 318 79.1 66.7 61.7 56.5 54.6 2.9 4 49 136 12 18 28 7 14 7 36 11
Type 2 1419 84.8 73.0 66.5 62.5 59.7 1.4 11 220 669 58 127 126 29 59 10 81 40
Type 3 2151 76.5 60.8 52.4 47.8 45.1 1.1 21 306 760 119 425 152 62 124 25 112 66
Type 4 779 62.1 41.9 30.0 23.4 20.4 1.5 10 65 133 37 363 11 31 54 7 35 43
Type 5 340 86.8 74.3 67.4 62.6 59.5 2.8 4 48 166 13 49 16 7 15 4 15 7
Table 10 Survival outcomes by histological differentiation
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Differentiated
type
6113 91.7 85.4 81.2 78.3 76.1 0.6 28 1120 3654 105 289 221 68 123 104 320 109
Undifferentiated
type
4935 84.9 75.4 70.1 66.6 64.6 0.7 34 723 2578 154 737 123 89 168 48 177 138
Other type 144 81.6 75.3 71.9 68.4 68.4 4.1 1 29 74 6 12 11 4 2 1 3 2
Table 7 Survival outcomes by tumor location
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
U 2399 86.0 76.7 71.3 67.5 65.3 1.0 13 370 1258 69 237 107 49 75 32 134 68
M 4351 92.2 87.1 83.3 80.8 78.9 0.6 23 760 2741 65 260 90 43 84 65 161 82
L 3936 89.4 81.4 77.1 74.2 71.9 0.7 21 685 2230 108 309 141 52 99 55 176 81
Whole 532 63.7 44.7 33.7 25.8 23.4 2.0 6 56 104 23 230 17 17 34 3 28 20
U upper third, M middle third, L lower third of stomach
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123Table 13 Survival outcomes by depth of invasion
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
pT1(M) 3071 98.1 96.9 95.0 93.5 92.2 0.5 5 606 2248 7 4 4 1 7 53 98 43
pT1(SM) 2662 97.5 95.0 93.1 90.9 89.1 0.6 6 500 1898 11 16 19 11 16 51 109 31
pT2(MP) 1071 93.4 88.7 84.0 80.9 78.3 1.3 3 183 675 13 23 31 19 22 17 68 20
pT2(SS) 1695 87.0 74.7 67.6 63.2 60.6 1.2 17 262 817 67 148 122 48 65 20 99 47
pT3(SE) 2278 69.7 50.9 41.3 35.8 33.0 1.0 26 264 601 132 712 140 72 148 10 102 97
pT4(SI) 417 57.7 38.1 30.0 26.0 22.8 2.2 5 45 77 36 134 39 8 40 4 24 10
p pathological ﬁnding, M mucosa or muscuralis musoca, SM submucosa, MP muscularis propria, SS subserosal, SE serosa, SI adjacent structures
Table 11 Survival outcomes by venous invasion (v)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
v0 6453 95.4 91.5 88.6 86.2 84.5 0.5 23 1228 4304 54 258 59 36 70 101 260 83
v1 2601 84.5 72.7 66.6 62.2 59.7 1.0 17 352 1276 103 365 115 53 112 29 127 69
v2 1347 75.7 59.8 50.4 45.8 42.6 1.4 17 168 463 71 271 95 44 74 16 84 61
v3 539 59.4 44.5 35.7 32.2 30.8 2.1 5 69 128 30 123 85 23 34 4 21 22
Table 12 Survival outcomes by lymphatic invasion (ly)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
ly0 4783 97.2 95.3 93.3 91.4 89.9 0.5 11 956 3389 10 48 23 11 35 80 177 54
ly1 2604 92.4 86.1 81.1 77.7 75.1 0.9 13 398 1606 51 187 84 36 37 40 115 50
ly2 2047 80.7 65.8 58.4 53.3 50.5 1.2 22 271 834 102 346 134 53 103 17 123 64
ly3 1481 65.2 45.4 36.3 31.6 29.4 1.3 16 194 334 95 438 110 57 110 13 77 53
Table 14 Survival outcomes by pT classiﬁcation
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
pT1 5733 97.8 96.0 94.1 92.3 90.8 0.4 11 1106 4146 18 20 23 12 23 104 207 74
pT2 2766 89.5 80.1 74.0 70.1 67.5 0.9 20 445 1492 80 171 153 67 87 37 167 67
pT3 2278 69.7 50.9 41.3 35.8 33.0 1.0 26 264 601 132 712 140 72 148 10 102 97
pT4 417 57.7 38.1 30.0 26.0 22.8 2.2 5 45 77 36 134 39 8 40 4 24 10
Table 15 Survival outcomes by lymph node metastasis (pN)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
pN0 6508 97.0 94.7 92.5 90.6 89.0 0.4 22 1240 4616 18 95 38 16 44 109 248 84
pN1 2274 84.7 72.3 66.2 61.3 58.3 1.1 12 322 1074 78 309 139 46 99 23 118 66
pN2 1703 72.1 52.8 41.4 35.8 33.4 1.2 19 224 439 103 442 135 69 109 13 100 69
pN3 421 53.8 33.1 25.8 22.0 17.4 1.9 4 33 61 60 136 37 28 35 3 13 15
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123unknown site (n = 298), and local recurrence including
node metastasis (n = 267).
The proportion of male patients was 69.6% and their
5YSR was lower than that of female patients (P\0.01;
Table 5; Fig. 5). The proportion of patients who were more
than 80 years old was 7.0%, and their 5YSR was 48.7%
(Table 6; Fig. 6). Upper-third gastric cancer accounted for
21.4% of the cases, and the 5YSR (65.3%) of patients with
cancer at this site was lower than that for the middle- and
lower-third cancers (P\0.001; Table 7; Fig. 7). The
Table 20 Survival outcomes by JGCA stage
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Stage IA 4997 98.2 96.7 94.9 93.2 91.9 0.4 11 983 3646 6 11 8 3 14 87 181 58
Stage IB 1459 96.4 93.0 90.1 87.4 85.1 1.0 7 267 993 9 28 13 11 15 28 78 17
Stage II 1237 93.0 85.0 79.7 75.7 73.1 1.3 7 196 736 26 70 44 24 38 14 65 24
Stage IIIA 975 85.8 71.2 61.2 55.2 51.0 1.7 9 143 395 47 137 50 32 53 6 61 51
Stage IIIB 562 76.6 55.3 43.9 36.0 33.4 2.1 5 63 153 48 141 31 24 40 2 36 24
Stage IV 1649 53.9 32.2 22.4 18.3 15.8 1.0 22 161 206 122 626 199 62 135 11 71 56
Table 16 Survival outcomes by liver metastasis (fH)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
fH0 10665 89.9 82.6 78.1 74.9 72.7 0.5 55 1806 6171 249 956 216 143 268 144 482 230
fH1 305 42.6 24.6 15.3 12.2 11.8 2.0 7 28 28 8 48 130 15 25 5 10 8
f ﬁnal ﬁnding
Table 17 Survival outcomes by peritoneal metastasis (fP)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
fP0 10301 91.2 84.5 80.0 76.9 74.8 0.4 49 1771 6131 232 628 322 143 245 148 468 213
fP1 658 49.0 27.0 19.3 14.7 12.4 1.4 11 64 66 24 363 30 15 49 1 21 25
Table 18 Survival outcomes by peritoneal cytology (CY)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
CY0 4109 88.6 78.9 73.0 68.9 66.4 0.8 24 671 2157 135 403 184 82 120 56 185 116
CY1 651 51.6 29.1 18.2 14.9 12.3 1.4 4 73 60 23 338 35 15 62 4 25 16
Table 19 Survival outcomes by distant metastasis (fM)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
fM0 10752 89.4 82.0 77.3 74.2 72.1 0.5 59 1817 6159 233 932 331 140 278 149 479 234
fM1 215 46.7 27.3 23.6 19.7 18.0 2.8 3 21 30 25 72 15 16 16 2 14 4
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123proportion of patients with type 4 cancer was 7.0%, and
their 5YSR was markedly low, at 20.4% (P\0.001;
Table 8;F i g .8). In regard to the histological type, the
5YSR of patients with undifferentiated type, including
poorly differentiated adenocarcinoma, signet-ring cell
carcinoma, and mucinous adenocarcinoma, was 64.6%.
The undifferentiated type showed a poorer prognosis than
the differentiated type (P\0.001; Tables 9, 10). The
grade of venous invasion (v0–v3) and that of lymphatic
invasion (ly0–ly3) showed signiﬁcant correlations with
prognosis (P\0.001; Tables 11, 12).
There was a high incidence of early-stage cancer, as
indicated in Tables 13 and 14 and Figs. 9 and 10.T h e
proportion of pathological T1 (pT1; mucosal or sub-
mucosal) cancer was 51.2%. The 5YSR of this popula-
tion was 90.8%, and the primary cause of death was
not cancer recurrence (n = 96), but other diseases
(n = 207).
Table 22 Survival outcomes by TNM stage
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Stage IA 4795 98.2 96.7 94.8 93.1 91.8 0.4 11 951 3489 6 11 9 3 13 81 175 57
Stage IB 1495 95.9 92.5 89.4 86.9 84.6 1.0 7 290 995 11 29 19 8 19 28 77 19
Stage II 1333 92.1 84.2 77.4 72.9 70.5 1.3 10 201 769 34 92 45 28 47 13 77 27
Stage IIIA 874 83.6 67.3 57.6 51.6 46.6 1.8 7 134 318 51 138 58 21 49 9 51 45
Stage IIIB 352 76.2 51.4 38.6 32.3 29.9 2.6 3 39 85 35 101 20 14 20 1 21 16
Stage IV 1638 55.3 33.2 23.9 19.0 16.6 1.0 21 157 219 120 605 186 79 128 11 68 65
Table 21 Survival outcomes by JGCA stage (4 classiﬁcations)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Stage I 6456 97.8 95.8 93.8 91.9 90.3 0.4 18 1250 4639 15 39 21 14 29 115 259 75
Stage II 1237 93.0 85.0 79.7 75.7 73.1 1.3 7 196 736 26 70 44 24 38 14 65 24
Stage III 1537 82.4 65.4 54.9 48.2 44.5 1.3 14 206 548 95 278 81 56 93 8 97 75
Stage IV 1649 53.9 32.2 22.4 18.3 15.8 1.0 22 161 206 122 626 199 62 135 11 71 56
Table 23 Survival outcomes by TNM stage (4 classiﬁcations)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Stage I 6290 97.7 95.7 93.5 91.7 90.1 0.4 18 1241 4484 17 40 28 11 32 109 252 76
Stage II 1333 92.1 84.2 77.4 72.9 70.5 1.3 10 201 769 34 92 45 28 47 13 77 27
Stage III 1226 81.4 62.7 52.1 46.0 41.8 1.5 10 173 403 86 239 78 35 69 10 72 61
Stage IV 1638 55.3 33.2 23.9 19.0 16.6 1.0 21 157 219 120 605 186 79 128 11 68 65
Table 24 Survival outcomes by approaches
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Laparotomy 10532 88.3 80.4 75.6 72.4 70.2 0.5 59 1757 5869 251 1002 345 154 289 147 487 231
Thoraco-
laparotomy
112 70.5 56.0 47.6 43.7 40.7 4.7 3 8 39 14 19 11 6 7 0 4 4
Laparoscopic 396 99.2 98.9 98.6 97.7 97.4 0.9 0 87 300 0 0 0 0 1 2 3 3
Others 2 100.0 50.0 50.0 50.0 50.0 35.4 0 0 1 0 0 0 0 0 0 1 0
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123Peritoneal washing cytology (CY) was carried out for
3481 of 5857 patients with T2, T3, and T4 cancer (59.4%).
The 5YSR of cytology-positive patients (CY1) was 12.3%,
which corresponded with that of the patients with perito-
neal metastasis (P1) (Tables 17, 18).
The 5YSRs of the patients stratiﬁed by the JGCA
staging system were 91.9% for stage IA, 85.1% for stage
IB, 73.1% for stage II, 51.0% for stage IIIA, 33.4% for
stage IIIB, and 15.8% for stage IV. These JGCA 5YSRs
seemed to correlate well with the TNM 5YSRs (Tables 20,
21, 22, 23; Figs. 12, 13).
In regard to the operative procedure, the proportion of
patients who underwent laparoscopic gastrectomy was
3.6%, and their 5YSR was 97.4%. Laparoscopic surgery
Table 25 Survival outcomes by operative procedures
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Distal
gastrectomy
6684 91.6 85.5 81.6 79.1 77.2 0.5 33 1173 4096 133 412 191 75 129 90 267 118
Total
gastrectomy
3377 80.0 67.5 60.6 56.1 53.7 0.9 25 512 1427 124 612 154 75 155 32 179 107
Proximal
gastrectomy
446 95.2 90.0 88.3 84.3 82.3 1.9 1 60 312 4 9 6 11 6 9 21 8
Pylorus-
preserving
277 96.7 95.2 94.4 92.0 90.4 1.8 2 32 220 1 2 3 0 2 5 6 6
Local excision/
segmental
resection
339 95.1 94.1 89.1 84.9 82.7 2.2 2 69 218 4 4 2 0 5 10 20 7
Mucosal
resection
138 94.4 89.5 84.3 80.8 78.0 3.8 0 31 81 1 1 1 0 1 9 8 5
Table 26 Survival outcomes by lymph node dissection (D)
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
D0 812 79.1 72.7 69.2 65.1 63.7 1.8 8 153 394 17 85 25 4 30 28 52 24
D1 2371 85.1 76.9 72.9 70.4 68.3 1.0 19 340 1326 48 236 83 31 74 46 137 50
D1?a 1368 91.3 85.8 82.2 79.6 77.5 1.2 5 292 799 26 69 40 15 28 17 68 14
D1?b 605 94.8 90.7 87.2 84.9 83.5 1.6 2 122 391 5 25 10 5 6 5 26 10
D2 5403 90.7 82.8 77.5 74.0 71.8 0.6 28 840 3147 134 523 166 81 142 53 183 134
D3 391 78.9 62.7 54.6 50.5 46.8 2.6 0 30 161 30 82 23 18 15 2 20 10
a, Lymph node No. 7 irrespective of the location of lesions, and additionally No. 8a in patients with lesions located in the lower third of the
stomach; b, Lymph nodes No. 7, 8a, 9
Table 27 Survival outcomes by involvement of the resection margins
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow
up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
PM-
and
DM-
10550 89.5 82.3 77.7 74.6 72.5 0.5 56 1784 6086 232 881 338 136 258 143 466 226
PM?
and/
or
DM?
332 58.5 39.4 32.2 24.5 22.3 2.4 6 34 59 22 119 12 19 31 5 20 11
PM proximal margin, DM distal margin
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123was carried out mainly in patients with early gastric cancer.
Only 1.0% of the patients were treated by thoraco-lapa-
rotomy, and their 5YSR was 40.7%. Thoraco-laparotomy
was carried out in patients with gastric cardia cancer
invading the esophagus (Table 24). Thirty percent of the
patients underwent total gastrectomy, and their 5YSR was
53.7%. The proportion of patients treated by modiﬁed
surgery such as proximal gastrectomy, pylorus-preserving
gastrectomy, segmental gastrectomy, and local resection
was 9.4% (Table 25). D0, D1, D1?a, and D1?b dissec-
tions were carried out in 7.4, 21.7, 12.5, and 5.5% of the
patients, respectively. According to the JGCA gastric
cancer treatment guidelines [7, 8], D1?a dissection with
modiﬁed gastrectomy was indicated for T1(M)N0 tumors
and T1(SM)N0 differentiated tumors\1.5 cm in diameter,
while D1?b dissection with modiﬁed gastrectomy was
indicated for T1(SM)N0 undifferentiated tumors,
T1(SM)N0 differentiated tumors larger than 1.6 cm,
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Table 28 Survival outcomes by curative potential of gastric resection
No. of
patients
Postoperative survival rate (%) SE of
5YSR
DD Lost to
follow up
Alive Main cause of death
1 year 2 year 3 year 4 year 5 year L P H M R OC OD UK
Resection A 7038 97.5 94.9 92.5 90.4 88.7 0.4 20 1309 5006 41 72 52 31 49 108 271 99
Resection B 2593 85.0 70.7 62.1 56.3 53.1 1.0 20 364 1108 121 380 151 72 119 31 157 90
Resection C 1420 50.3 28.7 19.7 15.5 13.4 1.0 22 145 145 98 567 152 55 128 10 65 55
Resection A, no residual disease with high probability of cure satisfying all of the following conditions: T1 or T2; N0 treated by D1, 2, 3 resection or N1
treated by D2, 3 resection; M0, P0, H0, CY0, and proximal and distal margins[10 mm; Resection B, no residual disease but not fulﬁlling criteria for
‘‘Resection A’’; Resection C, deﬁnite residual disease
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123T1(M)N1 tumors, and T1(SM)N1 tumors\2.0 cm. D0 and
D1 dissections were carried out mainly in patients with
non-curative factors or poor surgical risks. D2 lymph node
dissection was carried out in 49.3% of the patients and the
risk of direct death in those with D2 gastrectomy was 0.5%
(28/5403; Table 26).
Thecurativepotentialofgastricresectionwasanimportant
prognostic factor. The proportion of patients with a high
probability of cure (resection A) was 63.7%, and their 5YSR
was88.7%.Onthe otherhand,theproportionofpatients with
deﬁnite residual tumor (resection C) was 12.8%, and their
5YSR was 13.4% (Table 28; Fig. 14).
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123Discussion
The data presented in this report were collected from 187
hospitals in Japan. The number of new patients who were
diagnosed with gastric cancer in 2001 was estimated to be
107726 [9]. Accordingly, the 11261 patients registered by
this program corresponded to approximately 10% of the
population affected by gastric cancer in Japan. Even though
these patients may not represent the average features of
gastric cancer, this article is considered to be the largest
report for the past 10 years clarifying the trends of gastric
cancer.
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123The reliability of the results in this report depends on the
quality of data accumulated in the JGCA database. As the
algorithms of the JGCA staging system were rather com-
plicated, the error checking system on the data entry screen
did not work perfectly. In several categories, such as lymph
node metastasis (N), the JGCA code could not convert to
the TNM code automatically. A few ‘‘bugs’’ in the software
were revealed just after we had analyzed thousands of data
records. Therefore, the registration committee had to make
great efforts to cleanse and validate the raw data sent to the
data center from participating hospitals.
As compared with our archived data of 7935 patients
treated in 1991 [1], though the proportions of each stage
were similar, the direct death rate had signiﬁcantly
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123improved, dropping from 1.0 to 0.6% (P\0.001); the
proportion of patients aged more than 80 years old had
increased, from 4.5 to 7.0% (P\0.001); and the 5YSR of
stage IV had improved, from 9.0 to 15.8% (P\0.05).
These data suggest that, in this decade, the treatment results
may have improved in patients with advanced disease and
in older patients.
However, these data were retrospectively collected,
7 years after surgery. We had legal difﬁculties in regis-
tering personal information, which was essential for long-
term and prospective follow-up. The overall follow-up rate
in our program was 83.5%, as already mentioned. A lower
follow-up rate is generally considered to show misleading
results of higher survival rates in patients with advanced
disease. The Japanese Association of Clinical Cancer
Centers (consisting of 25 cancer center hospitals) has
reported that their follow-up rate was 98.5%, and the
5YSRs of 9980 patients who underwent surgery from 1997
to 2000 were 90.4% for TNM stage I, 67.8% for stage II,
43.3% for stage III, and 9.3% for stage IV [10]. On the
other hand, our 5YSR in stage IV patients was 16.6%
(Table 23). We might have overestimated our 5YSR in
stage IV patients, but we found that the follow-up rate
increased as the stage advanced; the follow-up rate of stage
IV patients was 90.4% (Table 29). Of the 187 participating
hospitals, 114 hospitals achieved high follow-up rates of
90% or more for stage IV patients. Therefore, the 5-year
follow-up rates and 5YSRs in these 114 hospitals were
calculated for reference. The mean follow-up rate for stage
IV patients in these 114 selected hospitals was 97.7% and
their 5YSR was 15.9% (Table 30). These data suggest that
the lower follow-up rate in our program may not have
serious effects on the 5YSRs. Although the correlation
between follow-up rate and survival rate is complicated, we
need to greatly improve our follow-up system to evaluate
our survival rates more accurately.
This is the ﬁrst nationwide report in which the JGCA
refers to peritoneal washing cytology (CY). CY was con-
ducted in 3481 (59.4%) of 5857 patients with T2, T3, or T4
cancer. The 5YSR of CY-positive (CY1) patients was
12.3% and their 5YSR was as poor as that of patients with
peritoneal metastasis (P1; 12.4%). Although CY was not
carried out commonly in 2001, it was regarded as a sig-
niﬁcant and independent prognostic factor.
The JGCA restarted a nationwide registration program
after an inactive period of 10 years. The most urgent pri-
ority of this program was to report detailed 5YSRs in
patients who had received a gastrectomy. Therefore, the
structure of the database was required to be simple and the
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Fig. 14 Kaplan–Meier survival
of the resected cases stratiﬁed
by curative potential of gastric
resection. Resection A,n o
residual disease with high
probability of cure satisfying all
of the following conditions: T1
or T2; N0 treated by D1, 2, 3
resection or N1 treated by D2, 3
resection; M0, P0, H0, CY0,
and proximal and distal margins
[10 mm; Resection B,n o
residual disease but not
fulﬁlling criteria for ‘‘Resection
A’’; Resection C, deﬁnite
residual disease
Table 29 Five-year follow-up rates stratiﬁed by TNM stage
No. of patients Lost to follow up FUR (%)
Stage I 6290 1241 80.3
Stage II 1333 201 84.9
Stage III 1226 173 85.9
Stage IV 1638 157 90.4
Total 10487 1772 83.1
FUR 5-year follow-up rate
Table 30 Follow-up rates and survival rates stratiﬁed by TNM stage
in 187 participating hospitals and 114 selected hospitals
TNM
stage
187 Participating hospitals 114 Selected hospitals
No. of
patients
FUR
(%)
5YSR
(%)
No. of
patients
FUR
(%)
5YSR
(%)
Stage IA 4795 80.2 91.8 3401 84.0 91.3
Stage IB 1495 80.6 84.6 1000 84.2 82.5
Stage II 1333 84.9 70.5 938 89.6 70.3
Stage IIIA 874 84.7 46.6 608 93.1 45.2
Stage IIIB 352 88.9 29.9 243 93.8 30.8
Stage IV 1638 90.4 16.6 1196 97.7 15.9
The 114 hospitals were selected on the criterion of achieving high
follow-up rate of 90% or more for stage IV patients
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123number of registration items was kept to a minimum. We
are now planning to register more items concerning rem-
nant gastric cancer, chemotherapy, and endoscopic sub-
mucosal dissection by upgrading the data entry software.
We will continue our efforts to collect qualiﬁed data
annually.
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Appendix: Member hospitals
Data of gastric cancer patients in this report were collected
from the surgical or gastrointestinal departments of the
following 187 hospitals (in alphabetical order).
Aichi Cancer Center Aichi Hospital, Aichi Cancer
Center Hospital, Akashi Municipal Hospital, Aomori City
Hospital, Asahikawa Medical University, Cancer Institute
Hospital, Chiba Cancer Center, Chiba University Hospital,
Dokkyo Medical University, Ebina General Hospital, Fu-
chu Hospital, Fujita Health University (Banbuntane Hou-
tokukai Hospital), Fujita Health University Hospital, Fukui
Red Cross Hospital, Fukui Saiseikai Hospital, Fukuoka
University Chikushi Hospital, Fukuoka University Hospi-
tal, Fukushima Medical University Hospital, Gunma Pre-
fectural Cancer Center, Gunma University Graduate School
of Medicine (Department of General Surgical Science),
Gunma University Graduate School of Medicine (Depart-
ment of Thoracic Visceral Organ Surgery), Hachioji
Digestive Disease Hospital, Hakodate Goryoukaku Hospi-
tal, Hakodate Municipal Hospital, Hamamatsu University
School of Medicine, Hamanomachi Hospital, Health
Insurance Naruto Hospital, Higashiosaka City General
Hospital, Himeji Central Hospital, Hirakata City Hospital,
Hiroshima City Hospital, Hiroshima Prefectural Hospital,
Hiroshima University Hospital, Hitachi General Hospital,
Hoshigaoka Koseinenkin Hospital, Hyogo Cancer Center,
Hyogo Prefectural Nishinomiya Hospital, Ibaraki Prefec-
tural Central Hospital, Ibaraki Seinan Medical Center
Hospital, Ichinomiya Municipal Hospital, Imamura Hos-
pital, Iwate Prefectural Central Hospital, Iwate Prefectural
Isawa Hospital, Iwate Prefectural Kamaishi Hospital, JA
Hiroshima Kouseiren Hiroshima General Hospital, Jichi
Medical University Hospital, Jikei University School of
Medicine (Aoto Hospital), Kagawa University Hospital,
Kakogawa Municipal Hospital, Kanagawa Cancer Center,
Kanazawa Medical University Hospital, Kawasaki Medical
School Hospital, Kawasaki Municipal Hospital, Keio Uni-
versity School of Medicine, Keiyukai Sapporo Hospital,
Kimitsu Chuo Hospital, Kinki Central Hospital, Kinki
University School of Medicine (Nara Hospital), Kiryu
Kosei General Hospital, Kitakyushu Municipal Medical
Center, Kitasato Institutional Hospital, Kitasato University
East Hospital, Kobe City Medical Center General Hospital,
Kobe University Hospital, Koga General Hospital, Kokura
Memorial Hospital, Kouchi Medical School Hospital,
Kumamoto Regional Medical Center, Kumamoto Univer-
sity Hospital, Kurashiki Central Hospital, Kurobe City
Hospital, Kushiro Rosai Hospital, Kyorin University Hos-
pital, Kyoto Prefectural University of Medicine, Kyoto
Prefectural Yosanoumi Hospital, Kyoto University Hospi-
tal, Kyushu University Hospital, Matsue City Hospital,
Matsushita Memorial Hospital, Matsuyama Shimin Hos-
pital, Minami Tohoku Hospital, Misawa City Hospital,
Mitoyo General Hospital, Mitsui Memorial Hospital,
Miyagi Cancer Center, Muroran General Hospital, Mu-
sashino Red Cross Hospital, Nagahama City Hospital,
Nagano Municipal Hospital, Nagaoka Chuo General Hos-
pital, Nagoya City University Hospital, Nagoya University
Hospital, Nanpuh Hospital, Nara Medical University Hos-
pital, Narita Red Cross Hospital, National Defense Medical
College, National Kyushu Cancer Center, NHO Ciba
Medical Center, NHO Ibusuki Hospital, NHO Kasumigaura
Medical Center, NHO Kobe Medical Center, NHO Naga-
saki Medical Center, NHO Osaka Medical Center, NHO
Sendai Medical Center, NHO Shikoku Cancer Center,
NHO Tokyo Medical Center, Niigata Cancer Center Hos-
pital, Niigata Prefectural Shibata Hospital, Niigata Uni-
versity Medical and Dental Hospital, Nippon Medical
School Chiba Hokusoh Hospital, Nippon Medical School
Musashikosugi Hospital, Nippon Medical School, NTT
West Osaka Hospital, Obihiro Tokushukai Hospital, Oita
Red Cross Hospital, Oita University Hospital, Okayama
Saiseikai General Hospital, Okayama University Hospital,
Okitama Public General Hospital, Onomichi Municipal
Hospital, Osaka City University Hospital, Osaka General
Medical Center, Osaka Kouseinenkin Hospital, Osaka
Medical Center for Cancer and Cardiovascular Diseases,
Osaka Red Cross Hospital, Otsu Municipal Hospital, Otsu
Red Cross Hospital, Ryukyu University School of Medi-
cine, Saga University Hospital, Sagamihara Kyodo Hospi-
tal, Saiseikai Fukuoka General Hospital, Saiseikai
Maebashi Hospital, Saiseikai Niigata Daini Hospital, Sa-
iseikai Noe Hospital, Saitama Medical Center, Saitama Red
Cross Hospital, Saitama Social Insurance Hospital, Sakai
Municipal Hospital, Saku Central Hospital, Sapporo Social
Insurance General Hospital, Sayama Hospital, Seirei
Hamamatsu General Hospital, Seirei Mikatahara General
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123Hospital, Self-defense Forces Central Hospital, Sendai
Open Hospital, Sendai Red Cross Hospital, Shiga Medical
Center for Adults, Shiga University of Medical Science,
Showa General Hospital, Showa University Toyosu Hos-
pital, Social Insurance Central General Hospital, Social
Insurance Kinan Hospital, St. Luke’s International Hospi-
tal, Suita Municipal Hospital, Surugadai Nihon University
Hospital, Tochigi Cancer Center, Toho University Ohashi
Medical Center, Tokushima Municipal Hospital, Tokushi-
ma University Hospital, Tokyo Dental College Ichikawa
General Hospital, Tokyo Medical University, Tokyo
Metropolitan Bokutoh Hospital, Tokyo Metropolitan Can-
cer and Infectious Disease Center Komagome Hospital,
Tokyo Metropolitan Police Hospital, Tokyo Women’s
Medical University (Institute of Gastroenterology), Tokyo
Women’s Medical University Hospital (Department of
Surgery 2), Tokyo Women’s Medical University Medical
Center East, Tonami General Hospital, Toranomon Hos-
pital, Tottori University Hospital, Toyama University
Hospital, Tsuchiura Kyodo General Hospital, Tsuruoka
Municipal Shonai Hospital, University of Fukui Hospital,
University of Miyazaki Hospital, University of Tokyo
Hospital, University of Yamanashi Hospital, Wakayama
Medical University, Yamagata Prefectural Central Hospi-
tal, Yamagata Prefectural Kahoku Hospital, Yamagata
University Hospital, Yamaguchi Rousai Hospital, Yaman-
ashi Prefectural Central Hospital, Yao Municipal Hospital,
Yodogawa Christian Hospital, Yokohama City University
Medical Center, Yuai Memorial Hospital.
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